Senseonics Holdings, Inc. Common Stock (NASDAQ:SENS) Receives Consensus Recommendation of “Moderate Buy” from Analysts

Senseonics Holdings, Inc. Common Stock (NASDAQ:SENS) has been given a consensus rating of “Moderate Buy” by the six research firms that are currently covering the stock, MarketBeat reports. One analyst has rated the stock with a sell rating, one has assigned a hold rating, three have issued a buy rating and one has assigned a strong buy rating to the company. The average 12 month price target among brokerages that have covered the stock in the last year is $17.00.

A number of brokerages have issued reports on SENS. Stifel Nicolaus cut their price target on shares of Senseonics Holdings, Inc. Common Stock from $9.00 to $8.00 and set a “hold” rating on the stock in a research note on Monday, May 11th. HC Wainwright reduced their target price on Senseonics Holdings, Inc. Common Stock from $18.50 to $14.00 and set a “buy” rating for the company in a research note on Tuesday, May 12th. Finally, Weiss Ratings cut Senseonics Holdings, Inc. Common Stock from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Thursday, May 28th.

Insider Activity at Senseonics Holdings, Inc. Common Stock

In other Senseonics Holdings, Inc. Common Stock news, Director Douglas A. Roeder acquired 22,686 shares of the business’s stock in a transaction dated Tuesday, May 12th. The shares were purchased at an average price of $5.56 per share, for a total transaction of $126,134.16. Following the completion of the purchase, the director directly owned 144,635 shares of the company’s stock, valued at $804,170.60. The trade was a 18.60% increase in their ownership of the stock. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. 4.70% of the stock is owned by company insiders.

Institutional Investors Weigh In On Senseonics Holdings, Inc. Common Stock

Several hedge funds have recently added to or reduced their stakes in SENS. Ausdal Financial Partners Inc. lifted its holdings in shares of Senseonics Holdings, Inc. Common Stock by 50.0% in the 3rd quarter. Ausdal Financial Partners Inc. now owns 105,000 shares of the company’s stock valued at $46,000 after buying an additional 35,000 shares during the period. GSK plc acquired a new stake in shares of Senseonics Holdings, Inc. Common Stock during the 4th quarter worth approximately $60,000. Townsend Asset Management Corp NC ADV acquired a new stake in Senseonics Holdings, Inc. Common Stock during the fourth quarter valued at $60,000. Kestra Advisory Services LLC acquired a new stake in shares of Senseonics Holdings, Inc. Common Stock during the 1st quarter valued at about $68,000. Finally, Sanctuary Advisors LLC purchased a new stake in shares of Senseonics Holdings, Inc. Common Stock in the fourth quarter valued at approximately $71,000. 12.36% of the stock is owned by hedge funds and other institutional investors.

Senseonics Holdings, Inc. Common Stock Trading Down 5.6%

Shares of SENS opened at $6.36 on Tuesday. The company has a debt-to-equity ratio of 1.05, a quick ratio of 3.19 and a current ratio of 3.51. The stock has a market cap of $265.85 million, a price-to-earnings ratio of -3.18 and a beta of 1.05. Senseonics Holdings, Inc. Common Stock has a 12 month low of $4.79 and a 12 month high of $12.58. The firm’s fifty day simple moving average is $6.51.

Senseonics Holdings, Inc. Common Stock (NASDAQ:SENS) last announced its earnings results on Thursday, May 7th. The company reported ($0.71) earnings per share for the quarter, missing the consensus estimate of ($0.65) by ($0.06). Senseonics Holdings, Inc. Common Stock had a negative return on equity of 129.97% and a negative net margin of 213.87%.The business had revenue of $11.71 million for the quarter. As a group, research analysts forecast that Senseonics Holdings, Inc. Common Stock will post -2.38 EPS for the current year.

Senseonics Holdings, Inc. Common Stock Company Profile

Senseonics Holdings, Inc develops and commercializes long-term implantable continuous glucose monitoring (CGM) systems for people with diabetes. The company’s primary product family is the Eversense system, which combines a small subcutaneously implanted sensor, a removable external transmitter, and companion smartphone applications to provide continuous glucose readings and alerts. Senseonics positions its technology as an alternative to wearable patch-style CGMs by offering multi-month sensor longevity and on-body vibration alerts delivered through the transmitter.

Senseonics supports clinical and commercial activities that include research and development, regulatory engagement, manufacturing and distribution, and training for healthcare providers who perform sensor insertion and removal.